YOLFTbeta
Universal Ibogaine Inc

Universal Ibogaine Inc

IBO · V · Healthcare / Biotechnology

0.005CAD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.005
Open0.005
Day Range0.005 – 0.005
52-Week Range0.005 – 0.015
Volume0
Market Cap1.56M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.02
Dividend Yield0.00%
Beta4.34
50-Day Avg0.005
200-Day Avg0.0053

About

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Nicholas Peter Karos
  • Employees0
  • Headquarters815 8th Avenue SW, Calgary, AB, Canada, T2P 3P2, Canada
  • Websitehttps://universalibogaine.com

Leadership

  • Mr. Nicholas Peter KarosCEO, Director of Capital Markets & Director
  • Mr. Shayne NyquvestCo-Founder
  • Cathy FernandesVP of Marketing & VP of Communications

Financials

Income Statement

Currency: CAD2018-07-312019-07-312020-07-312021-07-312022-07-312023-07-312024-07-31
Total Revenue00001.07M1.03M2.33M
Growth (%)------3.81%+126.32%
Cost of Revenue---0---
Gross Profit---0---
Operating Expense---77.41K---
Operating Income-176.23K-68.85K-59.24K-77.41K-4.75M-2.05M-901.11K
Operating Margin-----443.24%-199.10%-38.66%
EBITDA---58.99K-77.11K-10.16M-1.98M-1.54M
EBITDA Margin-----949.01%-191.87%-66.03%
Net Income-408.29K-98.11K-118.31K-290.65K-10.50M-2.39M-2.05M
Net Income Margin-----980.22%-232.08%-88.01%
R&D---63.20K409.31K9.21K91.77K
R&D as % of Total Revenue----38.22%0.89%3.94%
Interest Expense00015.01K67.74K118.13K168.95K
Interest Expense % of Total Revenue----6.33%11.47%7.25%

Balance Sheet

Currency: CAD2018-07-312019-07-312020-07-312021-07-312022-07-312023-07-312024-07-31
Total Assets320.66K217.21K116.61K2.20M6.32M5.50M4.51M
Total Liabilities25.44K20.09K21.72K2.20M2.37M3.75M3.52M
Total Equity295.22K197.12K94.89K-4.46K3.94M1.75M991.11K
Cash51.92K204.93K72.50K123.27K726.05K313.26K370.80K
Net Debt---267.80K1.01M2.42M2.20M

Cash Flow

Currency: CAD2018-07-312019-07-312020-07-312021-07-312022-07-312023-07-312024-07-31
Operating Cash Flow-320.34K-906.88K-2.33M-3.25M-4.33M-1.10M-838.61K
Investing Cash Flow--914.41K-42.93K-42.93K-2.09M--
Financing Cash Flow209.51K1.11M2.37M3.38M7.01M1.04M974.70K
Capital Expenditure0357.35K95.68K95.68K95.68K360.04K78.56K
Free Cash Flow-320.34K-71.99K-123.51K-206.13K-4.43M-1.46M-917.17K
FCF to OCF100.00%7.94%5.30%6.34%102.21%132.81%109.37%

Earnings

Report DateJan 9, 2026
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap1.56M
Enterprise Value4.01M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.76
Price / Book5.75
EPS-0.02
Book Value0.001
Revenue (TTM)2.06M
Gross Profit (TTM)356.65K
EBITDA-358.28K
Profit Margin-71.66%
Operating Margin-3.94%
Return on Equity-161.37%
Return on Assets-9.46%
Shares Outstanding312.86M
Shares Float303.14M
Beta4.34
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%